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Introduction: To investigate the impact of pre-existing radiological 
interstitial lung disease (ILD) findings on the incidence of radiation 
pneumonitis (RP) and clinical outcomes after stereotactic body radi-
ation therapy (SBRT) for stage I non–small-cell lung cancer.
Methods: We included 157 consecutive patients who underwent 
SBRT alone for stage I non–small-cell lung cancer and whose pre-
treatment lung computed tomography images were available for ret-
rospective review. The pretreatment computed tomography images 
were evaluated retrospectively for the presence of ILD. The incidence 
of RP, overall survival (OS) rate, and the incidence of disease pro-
gression and local progression were evaluated between patients with 
ILD (ILD[+]) and without ILD (ILD[−]).
Results: Pre-existing ILD was identified in 20 patients. The median 
follow-up period was 39.5 months. The incidences of RP worse than 
grade 2 (≥ Gr2 RP) and worse than grade 3 (≥ Gr3 RP) were signifi-
cantly higher in ILD(+) than ILD(−) (1 year ≥ Gr2 RP rate, 55.0% 
versus 13.3%; p < 0.001 and 1year ≥ Gr3 RP rate 10.0% versus 1.5%; 
p = 0.020). Multivariate analysis also indicated that ILD(+) was a 
risk factor for ≥ Gr2 and ≥ Gr3 RP, and the volume of the irradiated 
lung. The OS rate tended to be worse in ILD(+) than ILD(−) (3-year 
OS, 53.8% versus 70.8%; p = 0.28). No difference was observed in 
the disease progression or local progression rates.
Conclusions: Pre-existing ILD was a significant risk factor for symp-
tomatic and severe RP. Prescreening for ILD findings is important for 
determining the radiation pneumonitis risk when planning SBRT.
Key Words: Lung cancer, Stereotactic body radiation therapy, 
Interstitial lung disease, Radiation pneumonitis.
(J Thorac Oncol. 2015;10: 116–125)
The aim of stereotactic body radiation therapy (SBRT) is to achieve local control with a focal ablative dose confined 
to the tumor, sparing the surrounding tissues.1,2 Today, SBRT 
is considered a good option for stage I non–small-cell lung 
cancer (NSCLC) treatment, mainly for inoperable patients or 
those who refuse surgery. The results of several prospective 
multicenter phase II trials support the efficacy of SBRT.3–6
Radiation pneumonitis (RP) is the most frequent tox-
icity observed after SBRT. The reported incidence of symp-
tomatic RP after SBRT for peripherally located tumors ranges 
from 9.4 to 28%.7–11 Although the incidence of severe RP is 
usually low in most series,3–10 Yamashita et al.11 reported that 
three of the 25 patients died from grade-5 RP after SBRT. 
Later, they reported that pretreatment interstitial pneumonia 
shadows on computed tomography (CT) images and high val-
ues of serum Krebs von den Lungen-6 (KL-6) and Surfactant 
protein-D (SP-D) correlated with the high rate of severe RP.12 
Onishi et al.13 also noted the importance of pretreatment pul-
monary fibrosis findings and reported that 54% of those who 
developed fatal RP after SBRT had pretreatment pulmonary 
fibrosis. In the Japan Clinical Oncology Group (JCOG) 0403 
phase II trial, the presence of active interstitial change was 
defined as one of the exclusion criteria. Similarly, at our insti-
tution, those with interstitial changes are excluded as candi-
dates for SBRT in principle.
However, the incidence of ILD among lung cancer 
patients is higher than in the general population, because 
smoking is the common risk factor for both idiopathic pulmo-
nary fibrosis and lung cancer.14–16 It has been reported that the 
presence of ILD increased the incidence of postoperative acute 
respiratory distress syndrome and acute exacerbations17–19 and 
that ILD was a poor prognostic factor after surgery.20–24 Thus, 
lung cancer patients with ILD are not good candidates for sur-
gical resection. Because of its less invasive nature, SBRT for 
stage I NSCLC is mostly performed in patients with comor-
bidities—patients with ILD are sometimes considered for 
SBRT. To determine the optimal treatment for each early stage 
lung cancer patient with ILD, we need to know the incidence 
of RP and the prognosis after SBRT in patients with ILD.
In this study, we identified patients with pre-existing 
radiological ILD findings retrospectively among those who 
underwent SBRT at our institution and analyzed the impact of 
those findings on the incidence of RP and the clinical outcomes.
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PATIENTS AND METHODS
Patients
In total, 191 consecutive patients with stage I NSCLC 
who underwent SBRT at our institution from July 2004 to 
December 2011 were investigated retrospectively. Among 
them, those who satisfied the following criteria were included 
in the study: (1) treated with SBRT alone, (2) pretreatment 
CT images throughout the entire thorax with a lung window 
were available for retrospective review, and (3) the radiation 
pneumonitis and clinical course after treatment were evalu-
ated. In 29 patients, pretreatment CT images were not avail-
able, three patients received neoadjuvant chemotherapy, and 
two patients did not visit our hospital after SBRT. Thus, in 
total, 157 patients were entered into the study. The patient 
characteristics are presented in Table 1.
Written informed consent for the use of clinical data 
was obtained from all the patients. This retrospective study 
was approved by the Institutional Review Board.
Evaluation of ILD on Pretreatment CT Images
Pretreatment lung CT images for all included patients were 
available for review. The images were acquired with axial slice 
thicknesses of 7 to 10 mm. High-resolution CT images were also 
used for the entire lung in 69 patients and for the partial lung in 
83 patients. The images were evaluated by two physicians with 
a lung window (window level, −600 Hounsfield units; window 
width, 1500 Hounsfield units). The images were reviewed for 
CT findings usually present in ILD, such as honeycombing, 
subpleural reticular opacities, ground-glass opacity, and traction 
bronchiectasis.25,26 Patients with any of these findings suggestive 
of ILD on CT images were identified in the review process.
A board-certified thoracic radiologist examined the 
CT images of these patients to determine the presence of 
ILD in the patients and classified cases with ILD into a usual 
interstitial pneumonia (UIP) pattern and a non-UIP pattern 
when ILD was judged to be present. The classification was 
made according to the American Thoracic Society/European 
Respiratory Society (ATS/ERS) consensus classification of 
idiopathic interstitial pneumonia26 and the ATS/ERS/Japanese 
Respiratory Society/Latin American Thoracic Association 
statement on idiopathic pulmonary fibrosis.27
The severity of ILD was also evaluated using the scoring 
system proposed by Kazerooni et al.28: the sum of the 0 to 5 
scales for both alveolar and interstitial abnormalities, accord-
ing to the percentage of diseased area in each lobe. Because 
we included the patients who underwent lobectomies previ-
ously, the maximum score among all lobes was used for the 
evaluation instead of the total score. In this study, we defined 
those with a score of two or less (interlobular septal thick-
ening without honeycombing with/without minimal ground-
glass opacity) as minimal ILD and those with a score of three 
or more as significant ILD.
SBRT Procedure
Details of the SBRT procedure at our institution were 
described previously.29,30 The patients seen before April 2008 
were immobilized with a Stereotactic Body Frame (Elekta, 
Stockholm, Sweden); subsequently, the BodyFix system 
(Elekta) was used. The internal target volume was contoured 
using CT with a slow-scan technique with a rotation time of 4 
seconds, considering the tumor motion assessed using radio-
graph fluoroscopy. After June 2009, four-dimensional CT was 
used instead of slow-scan CT. The treatment plans were cre-
ated with Eclipse (Varian Medical Systems, Palo Alto, CA) 
using a pencil beam convolution algorithm with heterogeneity 
correction of Batho power law until June 2009, and then with 
iPlan (BrainLAB, Feldkirchen, Germany) and calculated using 
x-ray voxel Monte Carlo (XVMC). The planning target volume 
(PTV) was defined as the internal target volume with an addi-
tional 5-mm margin for set-up uncertainty. The treatment beam 
was collimated to the PTV with a 5-mm margin using a multi-
leaf collimator to ensure the peripheral dose of the PTV. In all 
cases, irradiation was applied with five to eight noncoplanar 
static beams with a 6-megavoltage radiograph using a Clinac 
2300 C/D (Varian Medical Systems) for patients treated before 
March 2008, a Novalis system (BrainLAB) from April 2008 to 
November 2010, and then a Vero4DRT system (MHI-TM2000; 
Mitsubishi Heavy Industries, Ltd., Hiroshima, Japan, and 
BrainLAB). The prescribed dose is shown in Table 1. The most 
frequent dose-fractionation was 48 Gy in four fractions at the 
isocenter (IC). For 24 patients with a centrally located tumor, 
60 Gy in eight fractions was applied at the IC. In those with 
T2a tumors, 56 Gy at the IC in four fractions for 10 patients, 50 
Gy to cover the 95% of PTV in four fractions for one patient, 
and 60 Gy to cover 95% of PTV in four fractions for one 
patient were used. All patients were set-up for skeletal anatomy 
using linac graphy or the ExacTrac kilovoltage imaging system 
(BrainLAB). To consider the effect of heterogeneity correc-
tion, the treatment plans made with Eclipse were recalculated 
using anisotropic analytical algorithm (AAA) (version 8.6.1; 
Varian Medical Systems) with the same monitor units as in the 
clinical plans. The irradiated lung volume more than 5 to 20 
Gy (Lung V5–20) and mean lung dose (MLD) were evaluated 
using the lung volume except the region overlapping PTV.
Follow-Up and RP Assessment
Regular follow-up visits and chest CT were performed 
as reported in our previous report.31 Local progression (LP) 
was diagnosed on the basis of enlargement of the local tumor 
on CT that continued for at least 6 months or histological con-
firmation. 18F-fluorodeoxyglucose positron emission tomogra-
phy was recommended when LP was suspected, but this was 
not required. To make a diagnosis of LP radiologically, the CT 
images were carefully evaluated to exclude consolidation due 
to radiation fibrosis. For patients who could tolerate salvage 
surgery, the LP was confirmed at surgical resection.
The severity of RP was graded according to Common 
Terminology Criteria for Adverse Events , version 3.0. In the 
patients who received salvage surgery or chemotherapy due to 
disease progression, the RP evaluation was conducted before 
any additional treatment.
Analysis
Between those with (ILD[+]) and without pretreatment 
radiological ILD findings (ILD[−]), the following clinical 
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TABLE 1.  Patient and Treatment Characteristics for All Patients; i.e., Those with ILD (ILD[+]), and Those without ILD (ILD[−])
Characteristics
All ILD(+) ILD(−) p Values
n = 157 n = 20 n = 137 ILD(+) vs. (−)
Age (years) 0.39
Mean [range] 77.5 [56–89] 78.4 [59–86] 77.3 [56–89]
Gender 0.28
  Male 115 17 98
  Female 42 3 39
ECOG PS 0.58
  0 79 12 67
  1 68 8 60
  2 8 0 8
  3 2 0 2
Smoking status (pack years) 0.017a
  0–40 69 4 65
  ≥40 84 16 68
  Not evaluated 4 0 4
Histology 0.14
  Adeno 69 7 62
  Sq 45 8 37
  LCLC 3 0 3
  NSCLC nos 14 4 10
  Unknown 26 1 25
T-stage 0.94
  T1a (≤ 20 mm) 58 7 51
  T1b(> 20 to ≤ 30 mm) 57 7 50
  T2a (> 30 to ≤ 50mm) 42 6 36
Tumor diameter (mm) 0.65
  Mean [range] 24.8 [10–45] 25.6 [11–40] 24.9 [10–45]
Pretreatment PFT
  %FVC < 80% / ≥ 80% 48/98 4/16 44/82 0.24
  FEV
1
 / FVC < 70% / ≥ 70% 86/60 7/13 79/47 0.034a
  Not evaluated 11 0 11
Pretreatment KL-6 (U/ml) <0.001a
  Mean [range] 357 [101–1030] 540 [237–1030] 317 [101–815]
  Not evaluated 72 5 67
Pretreatment LDH (IU/L) 0.72
  Mean [range] 197 [111–454] 191 [131–317] 198 [111–454]
Pretreatment CRP (mg/dl) 0.36
  Mean [range] 0.3 [0.0–3.9] 0.5 [0.0–3.9] 0.3 [0.0–3.6]
Total dose/fraction (prescribed to) 0.11
  48 Gy / 4 (IC) 121 14 107
  56 Gy / 4 (IC) 10 4 6
  60 Gy / 8 (IC) 24 2 22
  50 Gy / 4 (PTV D95) 1 0 1
  60 Gy / 4 (PTV D95) 1 0 1
PTV volume (cc) 0.33
  Mean [range] 37.1 [6.8–110.2] 39.9 [12.6–74.3] 36.7 [6.8–110.2]
aStatistically significant.
adeno, adenocarcinoma; CRP, C-reactive protein; D95, the dose to 95% of the volume; ECOG PS, Eastern Cooperative Oncology Group performance status; FVC, forced vital 
capacity; FEV
1
, forced expiratory volume in 1 s; IC, isocenter; ILD, interstitial lung disease; KL-6, Krebs von den Lungen-6; LCLC, large cell carcinoma; LDH, lactate dehydrogenase; 
NSCLC nos, non–small-cell lung cancer; PFT, pulmonary function test; PTV, planning target volume; Sq, squamous cell carcinoma.
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characteristics and treatment-related factors were compared 
using the Mann-Whitney U test, Fisher’s exact test, or the χ2 
test: age, gender, Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS), smoking status (0–40 versus ≥ 40 
pack years), histology, T-stage, tumor diameter, pretreatment 
percentage forced vital capacity (%FVC; <80% versus ≥ 80%), 
pretreatment forced expiratory volume in 1 second (FEV
1
) / 
FVC (<70% versus ≥ 70%), pretreatment serum KL-6, pretreat-
ment serum lactate dehydrogenase (LDH), pretreatment serum 
C-reactive protein (CRP), prescribed dose, and PTV volume.
The rates of RP and overall survival (OS) were esti-
mated by the Kaplan-Meier method, and the differences 
between the patient groups were assessed with the log-rank 
test. The rate of LP and disease progression (DP) were cal-
culated with the cumulative incidence function, account-
ing for nonlung cancer death as a competing risk, and the 
differences between the groups were evaluated using the 
Gray test. To evaluate the impact of ILD on the incidence 
of RP worse than grade 2 (≥ Gr2 RP) and RP worse than 
grade 3 (≥ Gr3 RP), univariate and multivariate analyses 
were performed with the Cox proportional hazards model 
using the following factors: ILD (ILD[+] versus ILD [−]), 
gender (male versus female), ECOG PS (2 or 3, versus 0 or 
1), smoking status (pack years, ≥ 40 versus < 40), pretreat-
ment %FVC (< 80% versus ≥ 80%), pretreatment FEV
1
/
FVC (< 70% versus ≥ 70%), fraction number (8 versus 4) 
and tumor location (upper or middle lobe versus lower lobe) 
as categorical data, and age (in years), biological effective 
dose based on α/β = 3 at IC, PTV volume, Lung V5–20, 
MLD, pretreatment CRP, and pretreatment LDH as continu-
ous data. Pretreatment KL-6 was excluded from the factors 
for univariate and multivariate analysis because there were 
too many missing values in this retrospective study. The 
factors with p < 0.20 in univariate analyses were included 
in the multivariate analysis with stepwise selection based 
on Akaike’s information criteria. For all analyses, the time 
from the first day of SBRT to the first observation of an 
event was used. Differences were deemed statistically sig-
nificant when p < 0.05. All statistical analyses were per-
formed using the R software (R Foundation for Statistical 
Computing, Vienna, Austria).32
RESULTS
ILD Findings and Severity
ILD findings were identified in 20 patients in the retro-
spective survey. Among the 20 patients in the ILD(+) group, 
11 patients had radiological UIP patterns and nine had non-
UIP patterns. Four patients had been diagnosed with ILD 
clinically before SBRT, and one patient had been diagnosed 
with UIP pathologically. One patient in the ILD(+) group had 
a history of rheumatoid arthritis.
The most severe ILD change was observed in the lower 
lobes for all the patients, and the maximum severity score was 
less than 2 for 12 patients, 3 for five patients, and 4 for three 
patients. Accordingly, 12 patients with a score of less than 2 
were classified as having minimal ILD and eight patients as 
having significant ILD.
Difference in the Clinical and Treatment-
Related Factors between ILD(+) and ILD(−)
The comparison of clinical characteristics and treat-
ment-related factors between the ILD(+) and ILD(−) groups 
is shown in Table 1. The pretreatment pulmonary function 
test (PFT) was available for 146 patients and the median 
interval between PFT and SBRT was 15 days. The values 
of pretreatment KL-6 were available only in 72 patients in 
this retrospective review. Between the ILD(+) and ILD(−) 
groups, statistically significant differences were observed in 
the percentage of smokers who smoked over 40 pack years 
(80.0% versus 51.1%, p = 0.017), the percentage of patients 
whose FEV
1
/FVC was lower than 70% (35.0% versus 62.7%, 
p = 0.034), and the values of pretreatment KL-6 (mean, 540 
versus 317 U/ml, p < 0.001). There was no significant dif-
ference in age, gender, ECOG PS, histology, T-stage, tumor 
diameter, pretreatment %FVC, pretreatment LDH, pretreat-
ment CRP, prescribed dose, and PTV volume.
RP Incidence with and without ILD
The median follow-up period was 39.5 (range, 4.2–116) 
months. The median times to the occurrence of Gr 2 RP and 
≥ Gr3 RP were 4.1 (range, 1.3–9.1) months and 3.0 (range, 
0.4–3.6) months, respectively. The observed worst RP grade 
and numbers in total, in the ILD(+) and ILD(−) groups are 
summarized in Table 2.
The cumulative incidence of ≥Gr2 RP was 18.7% (95% 
confidence interval [CI] = 13.4–25.8) for all patients, 55.0% 
(95% CI = 35.3–76.9) for the ILD(+) group, and 13.3% (95% 
CI = 8.6–20.3) for the ILD(−) group. The cumulative incidence 
of ≥Gr3 RP was 3.1% (95% CI = 1.2–6.7) for all the patients, 
10.0% (95% CI = 2.6–34.4) in the ILD(+) group, and 1.5% (95% 
CI = 0.4–5.8) in the ILD(−) group. The incidences of ≥Gr2 RP 
and ≥ Gr3 RP were both significantly higher in the ILD(+) group 
(p < 0.001 and p = 0.020, respectively; Fig. 1A, B).
The results of univariate and multivariate analyses 
for the incidence of ≥Gr2 RP and ≥Gr3 RP are shown in 
Table 3. The multivariate analysis indicated that ILD(+) was 
a significant factor for the increase in both ≥Gr2 RP and 
a potential factor for ≥Gr3 RP (hazard ratio = 5.52, 95% 
CI = 2.43–12.5; p < 0.001 and hazard ratio = 6.96, 95% 
CI = 0.98–49.7; p = 0.053). Other than ILD, ECOG PS, 
tumor location, and lung V5 was a significant factor for 
TABLE 2.  Numbers and Rates of Worst Radiation 
Pneumonitis Grade
RP Grade All ILD(+) ILD(−)
No. of Patients (%) n = 157 n = 20 n = 137
None 19 (12.1%) 1 (5.0%) 18 (13.1%)
Grade 1 109 (69.4%) 8 (40.0%) 101 (73.7%)
Grade 2 25 (15.9%) 9 (45.0%) 16 (11.7%)
Grade 3 1 (0.6%) 1 (5.0%) 0 (0%)
Grade 4 2 (1.3%) 1 (5.0%) 1 (0.7%)
Grade 5 1 (0.6%) 0 (0%) 1 (0.7%)
ILD, interstitial lung disease; RP, radiation pneumonitis.
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increases in ≥ Gr2 RP and lung V20 was a potential factor 
for increases in ≥ Gr3 RP.
Relationship Between RP Incidence 
and ILD Severity and Pattern
The patient who suffered grade-4 RP in the ILD(+) 
group was diagnosed clinically with interstitial pneumonia 
before treatment and had significant ILD findings with a non-
UIP pattern, reticulation, and ground-glass opacity. The pneu-
monitis findings were diffuse and irrelevant to the radiation 
field and were thus considered to be due to acute exacerba-
tions of the interstitial pneumonia (Fig. 2A, B). The cumula-
tive incidences of ≥ Gr2 RP and ≥ Gr3 RP were 62.5% (95% 
CI = 32.6–91.3) and 12.5% (95% CI = 1.9–6.13) for those 
with significant ILD and these values were increased signifi-
cantly versus the others (p < 0.001 and 0.027, respectively). 
For those with minimal ILD, the cumulative incidence of ≥ 
Gr2 RP was 50.0% (95% CI = 26.4–79.2) and significantly 
higher than the ILD(−) group (p < 0.001). However, the cumu-
lative incidence of ≥ Gr3 RP was 8.3% (95% CI = 1.2–46.1) 
and did not increase significantly (p = 0.10).
No difference was observed between the patients with 
UIP patterns and those with non-UIP patterns in the cumu-
lative incidence of ≥ Gr2 RP (45.5%, 95% CI = 22.0–77.1 
versus 66.7%, 95% CI = 27.7–92.2; p = 0.30) or ≥ Gr3 RP 
(9.1%, 95% CI = 1.3–49.2 versus 11.1%, 95% CI = 1.6–46.7; 
p = 0.85).
Clinical Outcomes
Three-year OS rate was 68.7% (95% CI = 60.6–75.4) for 
all the patients, 53.8% (95% CI = 29.9–72.8) for the ILD(+) 
group, and 70.8% (95% CI = 62.3–77.8) for the ILD(−) group. 
The OS rate in the ILD(+) group tended to be lower than 
that in the ILD(−) group, but not statistically significantly so 
(p = 0.28; Fig. 3A). The cumulative incidence of DP at 3 years 
was 39.0% (95% CI = 31.3–46.7) for all patients, 40.0% 
(95% CI = 18.6–60.7) for the ILD(+) group, and 38.9 % (95% 
CI = 30.5–47.1) for the ILD(−) group. The cumulative inci-
dence of LP at 3 years was 23.1% (95% CI = 16.5–30.3) for all 
the patients, 28.6% (95% CI = 9.7–51.0) for the ILD(+) group, 
and 22.3% (95% CI = 15.4–30.0) for the ILD(−) group. For DP 
and LP, no difference was observed between the ILD(+) and 
ILD(−) groups (p = 0.98 and 0.89, respectively; Fig. 3B, C).
DISCUSSION
As risk factors for RP after lung SBRT, several issues, 
including MLD, the volume of irradiated lung, PTV size, pre-
treatment KL-6, and pretreatment SP-D, have been investi-
gated.7–10,12,33 In addition, pre-existing interstitial pneumonia is 
thought to be a risk factor for fatal RP after SBRT,12,13 and has 
been reported in conventional radiotherapy.34,35
Our results showed that the presence of ILD was a 
significant risk factor for both ≥ Gr2 RP and ≥ Gr3 RP; 
the incidences of ≥ Gr2 RP and ≥ Gr3 RP for those with 
ILD were 55.0% and 10.0%, respectively. Even minimal 
ILD change was a significant risk factor for ≥ Gr2 RP—the 
incidence was 50.0%—but not for ≥ Gr3 RP. For patients 
with subclinical ILD who underwent surgical resection, 
postoperative acute respiratory distress syndrome showed 
an increase in those with subclinical idiopathic pulmonary 
fibrosis.18 Yamaguchi et al.36 reported that subclinical ILD 
findings in 16 patients had no significant impact on RP 
incidence after SBRT. Their subclinical ILD definition was 
similar to our minimal ILD. Their negative result may have 
been due to the small number of patients who had ≥ Gr2 
RP: in their cohort of 100 patients, only 13 had ≥ Gr2 RP. 
Because of this, they did not evaluate the risk factors for 
RP with multivariate analysis and did not evaluate clinical 
FIGURE 1.  Cumulative incidence of radiation pneumonitis worse than grade 2 (≥Gr2 RP) (A), and worse than grade 3 (≥ Gr3 
RP), (B), are shown in those with ILD (ILD[+]) and those without ILD (ILD[−]).ILD, interstitial lung disease.
121Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015  SBRT for Lung Cancer Patients with ILD
TA
B
LE
 3
. 
U
ni
va
ria
te
 a
nd
 M
ul
tiv
ar
ia
te
 A
na
ly
se
s 
of
 t
he
 In
ci
de
nc
e 
of
 R
P 
U
si
ng
 C
ox
 P
ro
po
rt
io
na
l H
az
ar
ds
 M
od
el
Fa
ct
or
≥
G
r2
 R
P
≥
 G
r3
 R
P
U
ni
va
ri
at
e 
A
na
ly
si
s
M
ul
ti
va
ri
at
e 
A
na
ly
si
s
U
ni
va
ri
at
e 
A
na
ly
si
s
M
ul
ti
va
ri
at
e 
A
na
ly
si
s
H
R
 (
95
%
 C
I)
p 
V
al
ue
s
H
R
 (
95
%
 C
I)
p 
V
al
ue
s
H
R
 (
95
%
 C
I)
p 
V
al
ue
s
H
R
 (
95
%
 C
I)
p 
V
al
ue
s
IL
D
<
 0
.0
01
a
<
 0
.0
01
a
0.
04
7*
0.
05
3
 
   (+
) 
vs
. (
−
)
5.
77
 (
2.
72
–1
2.
3)
5.
52
 (
2.
43
–1
2.
5)
7.
26
 (
1.
02
–5
1.
6)
6.
96
 (
0.
98
–4
9.
7)
G
en
de
r
0.
65
 
   M
al
e 
vs
. f
em
al
e
1.
22
 (
0.
52
–2
.8
4)
N
A
E
C
O
G
 P
S
0.
06
9
0.
00
2a
0.
87
 
   2 
or
 3
 v
s.
 0
 o
r 
1
2.
67
 (
0.
93
–7
.6
6)
5.
76
 (
1.
87
–1
7.
8)
1.
18
 (
0.
16
–8
.3
5)
S
m
ok
in
g 
st
at
us
0.
44
0.
43
 
   ≥4
0 
vs
. <
40
 (
pa
ck
 y
ea
rs
)
0.
75
 (
0.
36
–1
.5
6)
2.
48
 (
0.
26
–2
3.
9)
%
F
V
C
0.
99
0.
73
 
   <
80
%
 v
s.
 ≥
80
%
1.
00
 (
0.
45
–2
.2
3)
0.
67
 (
0.
07
–6
.4
4)
F
E
V
1/
F
V
C
0.
03
5a
0.
71
 
   <
70
%
 v
s.
 ≥
70
%
0.
44
 (
0.
20
–0
.9
4)
E
xc
lu
de
d
0.
69
 (
0.
10
–4
.8
7)
A
ge
0.
73
0.
59
 
   pe
r 
1-
ye
ar
 in
cr
ea
se
1.
01
 (
0.
95
–1
.0
7)
1.
05
 (
0.
88
–1
.2
5)
B
E
D
3 a
t I
C
0.
54
0.
52
 
   Pe
r 
10
 G
y 
in
cr
ea
se
1.
03
 (
0.
93
–1
.1
5)
1.
08
 (
0.
87
–1
.3
4)
Fr
ac
ti
on
 n
um
be
r
0.
41
0.
58
 
   8 
vs
. 4
1.
46
 (
0.
59
–3
.5
9)
1.
89
 (
0.
20
–1
8.
1)
Tu
m
or
 lo
ca
ti
on
<
 0
.0
01
a
0.
01
0a
0.
14
 
   U
pp
er
 o
r 
m
id
dl
e 
lo
be
 v
s.
 lo
w
er
 lo
be
3.
94
 (
1.
83
–8
.4
8)
2.
91
 (
1.
29
–6
.5
3)
5.
44
 (
0.
57
–5
2.
3)
E
xc
lu
de
d
P
T
V
 v
ol
um
e
0.
36
0.
08
3
 
   Pe
r 
1 
cc
 in
cr
ea
se
1.
01
 (
0.
99
–1
.0
2)
1.
03
 (
1.
00
–1
.0
7)
E
xc
lu
de
d
Ir
ra
di
at
ed
 lu
ng
 v
ol
um
e 
(p
er
 1
%
 in
cr
ea
se
)
 
   V
5
1.
10
 (
1.
04
–1
.1
6)
<
 0
.0
01
a
1.
09
 (
1.
03
–1
.1
4)
0.
00
2a
1.
07
 (
0.
94
–1
.2
3)
0.
27
 
   V
10
1.
02
 (
0.
99
–1
.0
4)
0.
23
1.
02
 (
0.
96
–1
.0
8)
0.
52
 
   V
15
1.
12
 (
1.
02
–1
.2
3)
0.
01
5a
E
xc
lu
de
d
1.
22
 (
0.
98
–1
.5
1)
0.
07
4
E
xc
lu
de
d
 
   V
20
1.
14
 (
1.
02
–1
.2
8)
0.
02
4a
E
xc
lu
de
d
1.
27
 (
0.
99
–1
.6
4)
0.
06
6
1.
25
 (
0.
98
–1
.6
0)
0.
07
2
 
   V
25
1.
17
 (
1.
02
–1
.3
4)
0.
03
1a
E
xc
lu
de
d
1.
33
 (
0.
98
–1
.8
0)
0.
67
M
L
D
0.
01
8a
0.
16
 
   Pe
r 
1 
G
y 
in
cr
ea
se
1.
22
 (
1.
04
–1
.4
3)
E
xc
lu
de
d
1.
31
 (
0.
90
–1
.9
2)
E
xc
lu
de
d
C
R
P
0.
22
0.
38
 
   Pe
r 
1 
m
g/
dl
 in
cr
ea
se
1.
34
 (
0.
84
–2
.1
6)
1.
59
 (
0.
56
–4
.5
5)
E
xc
lu
de
d
L
D
H
0.
81
0.
81
 
   Pe
r 
10
0 
IU
/L
 in
cr
ea
se
0.
90
 (
0.
37
–2
.1
7)
1.
27
 (
0.
18
–9
.1
5)
a S
ta
ti
st
ic
al
ly
 s
ig
ni
fi
ca
nt
.
B
E
D
3, 
bi
ol
og
ic
al
 e
ff
ec
tiv
e 
do
se
 b
as
ed
 o
n 
α
/β
 =
 3
; 9
5%
 C
I,
 9
5%
 c
on
fi
de
nc
e 
in
te
rv
al
; C
R
P,
 C
-r
ea
ct
iv
e 
pr
ot
ei
n;
 E
C
O
G
 P
S
, E
as
te
rn
 C
oo
pe
ra
tiv
e 
O
nc
ol
og
y 
G
ro
up
 p
er
fo
rm
an
ce
 s
ta
tu
s;
 ; 
F
E
V
1, 
fo
rc
ed
 e
xp
ir
at
or
y 
vo
lu
m
e 
in
 1
 ; 
F
V
C
, 
fo
rc
ed
 v
it
al
 c
ap
ac
it
y;
 H
R
, h
az
ar
d 
ra
ti
o;
 I
L
D
, i
nt
er
st
it
ia
l l
un
g 
di
se
as
e;
 L
D
H
, l
ac
ta
te
 d
eh
yd
ro
ge
na
se
; M
L
D
, m
ea
n 
lu
ng
 d
os
e;
 P
T
V,
 p
la
nn
in
g 
ta
rg
et
 v
ol
um
e;
 R
P,
 r
ad
ia
ti
on
 p
ne
um
on
it
is
 ,.
122 Copyright © 2014 by the International Association for the Study of Lung Cancer
Ueki et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
factors, like PFT. However, they suggested that the rate of 
extensive RP beyond the irradiated area was significantly 
increased for those with subclinical ILD.36 As for significant 
ILD, the cumulative incidences of ≥ Gr2 RP and ≥ Gr3 RP 
were increased significantly versus the others in our cohort. 
One grade-4 RP was observed in eight patients with sig-
nificant ILD and their radiological pattern was due to acute 
exacerbation of interstitial pneumonia. Our results suggest 
that the impact of ILD on RP depends on the severity of 
the ILD findings; thus, we should be more cautious when 
considering SBRT for those with significant ILD findings.
Other than the presence of ILD, lung V5 was identi-
fied as a significant risk factor for ≥ Gr2 RP and lung V20 
as a potential risk factor for ≥ Gr3 RP, consistent with sev-
eral reports about the relationship between the incidence of 
symptomatic RP and lung dose volume metrics.7–10 Thus, 
reducing the irradiated lung volume is also important and 
appropriate motion management is essential. Because it 
was difficult to recalculate the treatment plans with uni-
form algorithm, AAA or XVMC were used to evaluate the 
dose to normal lung. Both of AAA and XVMC are classi-
fied as Category 4 (electron transport and three-dimensional 
density sampling) method for heterogeneity correction in 
the report of task Group No. 65 of the Radiation Therapy 
Committee of the American Association of Physicists in 
Medicine37 and the mean difference in MLD, LungV5, and 
lung V20 between AAA and XVMC was reported as small as 
−0.08%, −1.11%, and −0.28%, respectively.38 Accordingly, 
the effect of the difference between two algorithms was 
thought to be negligible.
The biomarkers KL-6 and SP-D, reported as predicting 
factors for RP,12,33 could not be evaluated in the multivariate 
analysis in this retrospective study because there were too 
many missing values. However, relationships between ILD 
activity and values of KL-6 and SP-D have been shown in 
many studies.39–42 Consequently, those values are also consid-
ered to be useful in addition to the ILD findings.
As for the values of PFT, neither pretreatment FEV
1
/
FVC nor %FVC had any impact on the incidence of both ≥ 
Gr2 RP and ≥ Gr3 RP in multivariate analysis. Guckenberger 
et al.43 reported that there was no association between pre-
treatment PFT values and the incidence of RP. Our results 
showed that PFT was not an independent risk factor for 
symptoms of RP, but ILD was.
The presence of ILD was an unfavorable prognostic fac-
tor for patients with NSCLC treated with surgery or chemo-
therapy,22–24,44 as with our results. However, no difference was 
observed in the incidence of DP or LP between the ILD(+) 
and ILD(−) groups. In surgically treated patients, the rates 
of death due to respiratory failure were increased in patients 
with ILD, but not primary cancer death.20,45 The response to 
chemotherapy was reported to be identical in those with and 
without ILD.44 These results suggest that the poor progno-
sis in ILD(+) patients after treatment should be ascribed to 
the ILD itself. However, in our result, 3-year OS rate in the 
ILD(+) group was as high as 53.8%. The median survival 
of patients with T1 lung cancer is 13 months if untreated.46 
Accordingly, curative treatment should be considered for 
the patients with ILD. In our series, one of the 20 patients 
with ILD experienced grade-4 RP. This incidence is not more 
FIGURE 2.  CT images of the patients who had 
significant ILD findings and underwent SBRT for 
lung cancer situated in left segment 6. Before SBRT 
(A), and (B), on 5 days after the completion of SBRT 
when diagnosed as the acute exacerbation of ILD.
CT, computed tomography, ILD, interstitial lung 
disease; SBRT, stereotactic body radiation therapy.
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than the incidence of postoperative acute respiratory distress 
syndrome, 8.8% and 13%.18,23 Other than RP, life-threatening 
complications after SBRT are rare. Thus, if only the severity 
of ILD and the risk of RP were carefully evaluated, SBRT is 
a treatment option for those with ILD.
The limitations of our study should be mentioned. 
First, this was a retrospective study and selection bias may 
exist. The number of RP and patients with ILD findings 
were limited, because, in principle, those with clinically 
symptomatic ILD were excluded as candidates for SBRT. 
However, our study showed that the radiological ILD find-
ings were the risk factor for symptomatic and severe RP 
and suggested that the impact of ILD on RP depends on 
the severity of the ILD findings. It is important to assess 
the radiological ILD findings. Second, we could not perform 
the analysis using some factors, such as KL-6 or diffusing 
capacity for carbon monoxide, because there were too many 
missing values. A prospective multicenter study is needed to 
confirm our findings.
CONCLUSIONS
Pre-existing ILD was a significant risk factor for symp-
tomatic and severe RP. In addition, ILD tended to be a poor 
prognostic factor for survival. Prescreening for ILD findings 
is important for determining the radiation pneumonitis risk 
and selecting candidates for SBRT.
FIGURE 3.  A, Overall survival rate, (B) incidence of disease progression, and (C) incidence of local progression are shown in 
those with ILD (ILD[+]) and those without ILD (ILD[−]). ILD, interstitial lung disease.
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